Business
Senti Bio Appoints Feng Hsiung to Board of Directors
– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board o
About this update from Senti Biosciences Holdings, Inc.
[{"type":"image","alt":"Senti Biosciences, Inc.","displaySize":"","headline":null,"caption":"Senti Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LwHg6RoZ4drUhxxgTNKbZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf","width":166,"height":42}},"lazy":false},{"type":"text","content":"– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –","length":81,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the “Board”).","length":445,"tagName":"p"},{"type":"text","content":"“We are pleased to welcome Feng to our Board—he brings deep expertise in investment strategy and capital markets across multiple industries,” said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. “We look forward to the unique business perspectives he'll provide to Senti Bio as we execute on our strategic objectives and drive long-term growth.”","length":344,"tagName":"p"},{"type":"text","content":"Mr. Hsiung is the Founder, Chief Investment Officer, and Chief Executive Officer of Acion Partners, an investment advisor firm that has a strategic partnership with KKR and invests across industries. From 2007 through 2014, Mr. Hsiung was a Partner and the Chief Executive Officer (Asia) at York Capital. He started its Asia business as the initial employee in 2007, and launched and co-managed the York Asian Opportunities Master Fund. Mr. Hsiung is a member of the Young Presidents’ Organization since 2013 and the President of Raising Investment Corporation, the holding company for his family interests in freight forwarding and contract logistics. Mr. Hsiung holds a B.A. from Dartmouth College.","length":700,"tagName":"p"},{"type":"text","content":"Mr. Hsiung's appointment to the Board...